New results published in Frontiers in Neurology support ABCDx’s biomarker-clinical strategy for high-specificity LVO identification and strengthen the commercial positioning of LVOCheck
Geneva / Barcelona, 25 June 2026 — ABCDx is pleased to announce the publication of a peer-reviewed article in Frontiers in Neurology presenting key clinical results supporting the scientific and commercial foundation of LVOCheck, the company’s point-of-care solution under development for large vessel occlusion stroke triage.
The article, entitled “High-specificity identification of large vessel occlusion stroke using D-dimer and NT-proBNP combined with clinical variables”, represents a major milestone for ABCDx. It is the first publication of these LVOCheck-related results in an impactful peer-reviewed neurological journal and provides independent scientific validation of the company’s multimodal strategy.
Large vessel occlusion is one of the most severe forms of ischemic stroke and is associated with a disproportionate share of stroke-related disability, mortality and healthcare costs. Mechanical thrombectomy can dramatically improve outcomes, but access to treatment remains highly time dependent. Rapidly identifying patients with a high probability of LVO before hospital arrival is therefore a major unmet need in acute stroke care.
The published study analyzed 290 patients with suspected acute ischemic stroke, including 96 patients with confirmed LVO. The results show that a multimodal panel combining NT-proBNP, D-dimer, mean blood pressure and NIHSS significantly improves high-specificity LVO identification compared with individual biomarkers, clinical variables alone, or other evaluated biomarker-clinical combinations.
At a predefined high-specificity threshold, the panel achieved:
-59.8% sensitivity at 90% specificity in the full 24-hour cohort
-65.7% sensitivity at 90.3%specificity in patients presenting within 6 hours of symptom onset
These results are highly relevant for real-world stroke triage, where specificity is critical to avoid unnecessary bypass of primary stroke centers while identifying patients who may benefit from direct routing to thrombectomy-capable centers.
Importantly, the publication supports ABCDx’s differentiated approach: combining blood biomarkers, clinical variables and algorithmic interpretation into a dedicated point-of-care workflow. This multimodal strategy is designed to provide actionable decision support in time-critical emergency settings, including ambulances, emergency departments and stroke networks.
ABCDx believes these results position LVOCheck ahead of currently reported competing approaches in terms of high-specificity clinical performance and technological differentiation. Unlike single-marker or purely clinical scale-based approaches, LVOCheck is built on a multimodal model that captures complementary biological and clinical dimensions of LVO pathophysiology, including coagulation activation, cardiac stress, hemodynamic status and neurological severity.
The company has also secured exclusive licences to the underlying intellectual property, already granted in several territories, providing a strong proprietary position around the biomarker combinations and diagnostic strategy supporting LVOCheck. This IP foundation strengthens ABCDx’s competitive advantage and supports the company’s commercial strategy in the acute stroke diagnostics market.
“This publication is a major value-creation milestone for ABCDx,” said Prof. Jean-Charles Sanchez, CEO and Co-founder of ABCDx. “It provides peer-reviewed evidence that our multimodal biomarker-clinical strategy can address one of the most important unmet needs in stroke care: identifying patients with a high probability of large vessel occlusion early enough to improve triage and access to thrombectomy. Combined with our exclusive IP position and our point-of-care development strategy, these results further strengthen the commercial potential of LVOCheck.”
The authors emphasize that the panel should be interpreted as a rule-in enrichment strategy to identify patients with a high probability of LVO, rather than as a rule-out test to exclude LVO in lower-risk patients. This positioning is fully aligned with ABCDx’s intended use for LVOCheck as a decision-support tool within established stroke care pathways.
The publication also highlights the feasibility of translating this biomarker-clinical panel into a dedicated point-of-care platform for prospective evaluation in emergency medical service settings, including assessment of analytical reliability, turn around time and integration into operational stroke workflows.
ABCDx thanks all authors, clinical investigators, emergency teams and research partners involved in this important work, including the University of Geneva, ABCDx, IBiS / Virgen Macarena and Virgen del Rocío University Hospitals, Vall d’Hebron Institute of Research, and the Andalusian Emergency Medical Service.
Reference
Azurmendi L.,Gonzalez-Fraile J., Barragán-Prieto A., Reymond S., Delgado R.M., de Jesús-GilC., Penalba A., Cabezas-Rodríguez J.A., Moniche F., Pérez-Sánchez S.,González-Garcia A., Montaner J. and Sanchez J.C.
High-specificity identification of large vessel occlusion stroke using D-dimer and NT-proBNP combined with clinical variables.
Frontiers in Neurology, 2026.
About ABCDx
ABCDx is a Swiss-Spanish diagnostics company developing blood-based and digital solutions to support faster decision-making in acute brain injury, including stroke and traumatic brain injury. The company is developing a point-of-care diagnostic platform combining biomarkers, clinical data and algorithmic interpretation to bring actionable information closer to the patient and support faster triage, treatment and care pathway decisions.
Media Contact
Tamara Sefcovicova
PR, Marketing and Office Operations Specialist
